A clinical trial referral can lead to discussions about research participation, eligibility, and potential care options. The next step may change after the patient meets with a research team. The patient may not meet the study’s eligibility criteria, decide not to participate, or find that the trial is no longer suitable after further evaluation.
For community oncology practices, these situations raise an important operational question: what happens to the care plan when a patient does not enroll in a clinical trial?
Planning the next step may involve discussing the patient’s preferences, coordinating communication between clinicians, and clarifying responsibilities for follow-up.
The community oncologist may continue managing the patient’s cancer care, coordinate with a specialist, or work with the research team to clarify relevant findings, depending on the circumstances.
A referral that does not lead to enrollment may still produce information relevant to subsequent care discussions. When sharing is appropriate and permitted, that information can help participating clinicians clarify what was reviewed and which questions remain open.
Why Clinical Trial Non-Enrollment Needs a Clear Care Plan
Clinical trials have eligibility criteria that may relate to cancer type, disease stage, prior treatment, laboratory findings, medical history, or other factors. Initial trial matching does not establish eligibility; the research team evaluates eligibility under the study’s criteria and applicable procedures. The National Cancer Institute provides background on how clinical trials work.
A patient may also decide that participation does not fit their preferences, circumstances, or understanding of the study. Travel, scheduling, additional testing, treatment concerns, and the practical demands of research participation may influence the decision. These concerns deserve discussion without implying that a patient has made the wrong choice.
Non-enrollment can reflect clinical, personal, or logistical factors. The next discussion can take these circumstances into account alongside the available information, the patient’s preferences, and the treating clinicians’ assessment.
A documented plan can help clarify three practical questions:
- What was learned during the trial evaluation?
- Who will discuss the next care options with the patient?
- Which clinicians need relevant updates to continue coordinating care?
These questions are about care planning rather than persuading a patient to enroll. They also help the community practice understand what occurred after the referral and how that information may affect subsequent discussions.
Common Reasons a Patient May Not Enroll
The study’s eligibility criteria are not met
Clinical trials have defined inclusion and exclusion criteria. A patient may initially appear to fit a study’s general purpose but later be found ineligible after medical records, test results, or other required information are reviewed.
The community oncologist and research team may need to clarify which evaluation findings can be shared, subject to applicable consent and privacy requirements, and whether those findings are relevant to the patient’s ongoing care discussion.
Not meeting the eligibility criteria for one study does not establish whether another research option is suitable or which treatment should follow. Further consideration depends on the patient’s clinical circumstances and discussion with their treating clinicians.
The patient chooses not to participate
A patient may decide against a trial after learning about its requirements, potential risks, possible benefits, or practical demands. Because participation is voluntary, the discussion should respect the patient’s preferences and provide understandable information about available options.
The discussion should not frame a decision against enrollment as a failure. Instead, clinicians can ask what concerns influenced the decision and whether the patient would like to discuss other available care options. The discussion should support an informed decision without pressuring the patient to reconsider.
The study is no longer a suitable option
A patient’s clinical circumstances or the study’s availability may change between the initial discussion and the enrollment decision. Further evaluation may affect the suitability of the study, or the research site may determine that the study cannot proceed for that individual.
When a patient is no longer eligible for a study or decides not to continue, the research team and referring practice can clarify the transition back to the patient’s ongoing care, as appropriate. The next discussion may address relevant findings, outstanding questions, and the roles of the clinicians involved.
What Should Happen After a Patient Does Not Enroll?
The following framework is intended to support operational planning. It is not a clinical protocol, and the appropriate steps depend on the patient’s situation, clinician judgment, and local processes.
1. Clarify the status of the trial evaluation
The community practice needs a clear understanding of whether the patient was screened, found ineligible, chose not to proceed, or stopped the process for another reason. These situations are different and may require different follow-up conversations.
An update from the research team, where available and permitted, can clarify the evaluation status, shareable findings, and outstanding communication needs. This information can provide context for the next care discussion.
2. Confirm who will discuss the next steps with the patient
Patients may receive information from a community oncology practice, an academic center, and a clinical research team. When responsibilities are unclear, patients may have questions about whom to contact or which clinician will discuss the next phase of care.
The clinicians involved can clarify who will communicate the trial evaluation results, who will discuss available care options, and how follow-up questions will be handled. Responsibilities should reflect the care arrangement and the patient’s preferences, without assuming that the patient will return to a particular physician.
3. Review what the evaluation adds to the care discussion
Trial screening may produce information that is relevant to subsequent discussions. Whether that information affects care depends on its nature and clinical significance. The treating clinician can review relevant records and determine whether further assessment or discussion is appropriate.
A structured summary can help the team identify what has been reviewed, which questions remain open, and whether another specialist perspective may be useful.
Clinical decisions remain with the responsible clinicians and the patient, based on the patient’s circumstances and preferences. The operational goal is to make the relevant information available for that conversation.
4. Document the agreed-upon next step
A care plan following non-enrollment can record the current status, the clinician responsible for the next discussion, any information still needed, and the intended communication route. Documentation should follow the practice’s procedures and applicable privacy requirements.
The record does not need to predict what will happen next. It should reflect what has been agreed upon and identify outstanding questions without suggesting that unresolved matters have already been settled.
When more than one care setting is involved, documentation can record whether another discussion is planned, a specialist update is pending, or the current care plan remains under the community practice’s direction.
Respecting Patient Choice While Maintaining Communication
A decision not to enroll can involve uncertainty, disappointment, relief, or competing personal priorities. Patients may need time to process information before deciding how they want to proceed. Communication should make room for questions and avoid presenting research participation as the only meaningful next step.
The American Society of Clinical Oncology’s 2026 patient-clinician communication guideline addresses communication across cancer care, including treatment discussions and communication between clinicians. It also emphasizes tailoring information to patients’ needs and supporting shared decision-making.
For community oncology teams, this can translate into a few practical habits:
- Explain the status of the trial evaluation in plain language.
- Ask what matters to the patient as they consider the next step.
- Clarify which clinician will address follow-up questions.
- Record relevant decisions and communication plans in the appropriate clinical record.
The wording used matters. Describing a patient as having “failed” to qualify can make an eligibility decision sound personal. Neutral language such as “the patient did not meet the study’s eligibility criteria” keeps the focus on the study requirements rather than assigning blame.
When a patient declines participation, document the decision neutrally without implying noncompliance or discouraging discussion of available options.
Keeping Community and Academic Clinicians Connected
When trial evaluation takes place at an academic center or another research institution, the community oncologist may have an ongoing role in the patient’s care. The specific arrangement depends on the patient’s needs and the responsibilities agreed upon by the participating clinicians.
A non-enrollment decision can prompt a review of communication between community and academic clinicians. The discussion may cover which findings can be shared, who will address outstanding questions, and how relevant updates will be documented in the patient’s care record.
Community and academic teams may have different responsibilities and areas of expertise, depending on the patient’s circumstances. Practices can review whether participating clinicians understand their roles and have an appropriate process for exchanging relevant information.
A shared care model provides a framework for communication when clinicians across care settings have different responsibilities. It supports coordination without prescribing a single care pathway or replacing clinical judgment.
For practices managing referrals across institutions, useful questions include:
- Is there a defined way to communicate the outcome of a trial evaluation?
- Do the involved clinicians understand who will discuss the next step?
- Can relevant case information be reviewed without unnecessary duplication?
- Is there a process for clarifying questions between community and academic teams?
These are operational questions rather than promises about clinical results. Their purpose is to help practices identify gaps in communication and determine whether their existing processes need refinement.
Where Case Prep and Oncology Infrastructure Fit
Care planning after non-enrollment depends partly on how clinical information is assembled, reviewed, and communicated. When information sits across separate records, messages, or referral documents, clinicians may need additional coordination to understand the status of the case.
Case Prep can support the organization of relevant case information for physician review. Within a broader oncology collaboration workflow, it can bring case preparation, Curbside Consults, and clinical trial matching into a connected process. Trial matching is one component of that work, rather than the sole purpose of the infrastructure.
The value of a structured workflow is not that it determines a treatment decision or guarantees a particular next step. Rather, it provides a way to prepare relevant information and support physician-to-physician discussion when additional context is needed.
1104Health’s Oncology Collaboration Network focuses on collaboration between community and academic oncology settings through Case Prep, Curbside Consults, Roundtables, and shared-care coordination. Clinical trial matching is one component of this broader infrastructure.
Roundtables provide a setting for regional physicians to discuss case-specific questions and collaboration across community and academic practices.
These discussions are distinct from decisions about an individual patient’s care, which remain with the treating clinicians and the patient.
Building a More Deliberate Process for Non-Enrollment
Practices can review how they receive updates from research sites, document referral outcomes, and identify the clinician responsible for the next patient discussion. This review can help teams identify whether communication responsibilities, access to relevant information, or next steps need clarification.
The aim is to understand where coordination breaks down and make targeted adjustments that fit the practice’s workflow.
This process should also be reviewed with attention to patient consent, information-sharing policies, and the responsibilities of participating organizations. Clinical information should be exchanged through appropriate channels, and documentation should reflect the permissions and requirements that apply to the case.
After non-enrollment, a patient may continue care with the community oncology practice, consult another specialist, consider another research option, or discuss a different plan with the treating clinicians. The appropriate next step depends on the patient’s circumstances.
For that reason, a referral process should account for what happens when enrollment does not occur—not just whether a patient reaches a trial site. Clear communication, role definition, and organized case information can help clinicians coordinate the next discussion without making assumptions about what the patient will choose.
Conclusion
When a patient does not enroll in a clinical trial, the care conversation continues. The reason may be eligibility, patient preference, study availability, or another factor that changes the original plan. Each situation calls for an appropriate discussion grounded in the patient’s circumstances and the clinical team’s assessment.
Community oncology practices can plan for these transitions by clarifying the referral outcome, identifying who will communicate with the patient, reviewing relevant information, and documenting the agreed-upon next step across participating care settings.
For 1104Health, this is part of a broader infrastructure question: how can oncology practices support physician collaboration and shared-care coordination beyond the initial referral? Case Prep, Curbside Consults, Roundtables, and the Oncology Collaboration Network are relevant to this discussion, while clinical decisions remain with the patient and treating clinicians.
The aim is to clarify how participating clinicians can communicate about next steps in light of the patient’s circumstances and preferences, without assuming whether the patient will enroll or continue care with a particular practice.
Frequently Asked Questions
1. What happens when a patient is not eligible for a clinical trial?
The research team can explain the eligibility assessment and share relevant findings when permitted. The treating clinicians can review available information and discuss possible next steps with the patient in light of the clinical circumstances.
2. What if a patient decides not to participate in a clinical trial?
The patient’s decision should be respected. The treating team can discuss the patient’s concerns and preferences, explain available care options, and clarify who will handle subsequent questions.
3. Does a clinical trial referral end the community oncologist’s role?
A clinical trial referral does not, by itself, establish whether the community oncologist’s role will change. Ongoing responsibilities depend on the care arrangement, the patient’s circumstances, and communication among the clinicians involved.
4. What information should be communicated after non-enrollment?
Relevant information may include the evaluation status, findings that may be shared, outstanding questions, and the planned communication step. Information sharing should follow applicable consent requirements, privacy rules, and local procedures.
5. How can a practice document a trial referral that did not lead to enrollment?
The practice can document the outcome, relevant information received, the clinician responsible for the next discussion, and any unresolved coordination tasks. Documentation should reflect the actual plan rather than assume a future decision.
6. How does a shared care model relate to clinical trial non-enrollment?
A shared care model can help participating clinicians consider their respective roles and communication needs when care spans community and academic settings. It supports coordination without prescribing a specific clinical decision.
7. What role can Case Prep play after a trial evaluation?
Case Prep can help organize relevant case information for physician review and discussion. It does not determine eligibility, select treatment, or replace the judgment of the treating clinicians.
8. How does 1104Health relate to this challenge?
1104Health focuses on oncology infrastructure and collaboration between community and academic clinicians. Its Oncology Collaboration Network includes Case Prep, Curbside Consults, and Roundtables, with an emphasis on organizing case information and supporting shared-care coordination across participating settings.
